Todd Brady'un ücretlendirmesi Aldeyra Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$45m
Jun 30 2024	n/a	n/a	-US$38m
Mar 31 2024	n/a	n/a	-US$30m
Dec 31 2023	US$4m	US$581k	-US$38m
Sep 30 2023	n/a	n/a	-US$46m
Jun 30 2023	n/a	n/a	-US$52m
Mar 31 2023	n/a	n/a	-US$61m
Dec 31 2022	US$3m	US$559k	-US$62m
Sep 30 2022	n/a	n/a	-US$65m
Jun 30 2022	n/a	n/a	-US$66m
Mar 31 2022	n/a	n/a	-US$63m
Dec 31 2021	US$3m	US$547k	-US$58m
Sep 30 2021	n/a	n/a	-US$53m
Jun 30 2021	n/a	n/a	-US$46m
Mar 31 2021	n/a	n/a	-US$39m
Dec 31 2020	US$2m	US$544k	-US$38m
Sep 30 2020	n/a	n/a	-US$39m
Jun 30 2020	n/a	n/a	-US$49m
Mar 31 2020	n/a	n/a	-US$55m
Dec 31 2019	US$4m	US$523k	-US$61m
Sep 30 2019	n/a	n/a	-US$58m
Jun 30 2019	n/a	n/a	-US$50m
Mar 31 2019	n/a	n/a	-US$46m
Dec 31 2018	US$3m	US$506k	-US$39m

Tazminat ve Piyasa: Todd 'nin toplam tazminatı ($USD 3.68M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.24M ).

Tazminat ve Kazançlar: Todd şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Todd Brady (52 yo)

13yrs

Görev süresi

US$3,684,651

Tazminat

Dr. Todd C. Brady, M.D., Ph D., served as a Director at F-star Therapeutics, Inc from November 20, 2020 to March 2023. He has been the Chief Executive Officer and President of Aldeyra Therapeutics, Inc. si...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Todd Brady	CEO, President & Director	13yrs	US$3.68m	1.94% $ 6.3m
Stephen Machatha	Chief Development Officer	4yrs	US$1.59m	0.19% $ 609.1k
Michael Alfieri	Principal Financial & Accounting Officer	less than a year	Veri yok	Veri yok
David Burke	Head of Investor Relations	no data	Veri yok	Veri yok
Laura Nichols	Operations Manager	no data	Veri yok	Veri yok

4.0yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: ALDX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Todd Brady	CEO, President & Director	20yrs	US$3.68m	1.94% $ 6.3m
Richard Douglas	Independent Chair of the Board	8.3yrs	US$221.98k	0.21% $ 681.3k
Ben Bronstein	Independent Director	14.6yrs	US$190.40k	0.047% $ 154.0k
Gary Phillips	Independent Director	15.7yrs	US$194.07k	0.025% $ 80.7k
Martin Joyce	Independent Director	11.3yrs	US$195.66k	0.040% $ 130.6k
Neal Walker	Independent Director	11.6yrs	US$174.22k	0.027% $ 86.4k
Jay Duker	Member of Retina Segment Scientific Advisory Board	no data	Veri yok	Veri yok
Paul Karpecki	Member of Anterior Segment Scientific Advisory Board	5yrs	Veri yok	Veri yok
John Sheppard	Member of Anterior Segment Scientific Advisory Board	no data	Veri yok	Veri yok
Nancy Miller-Rich	Independent Director	5yrs	US$174.22k	0% $ 0
Victor Perez	Member of Anterior Segment Scientific Advisory Board	no data	Veri yok	Veri yok
David Chu	Member of Anterior Segment Scientific Advisory Board	no data	Veri yok	Veri yok

11.4yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ALDX 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 11.4 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/06 05:11
Gün Sonu Hisse Fiyatı	2025/01/06 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Aldeyra Therapeutics, Inc. 22 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Raghuram Selvaraju	Aegis Capital Corporation
Keay Nakae	Ascendiant Capital Markets LLC
Esther Lannie Hong	Berenberg

Aldeyra Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Chief Development Officer recently sold US$76k worth of stock

Chief Development Officer notifies of intention to sell stock

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 04, 2024

CEO, President & Director recently sold US$581k worth of stock

CEO, President & Director notifies of intention to sell stock

CEO, President & Director exercised options and sold US$492k worth of stock

Recent updates

New minor risk - Profitability

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Chief Development Officer recently sold US$76k worth of stock

Chief Development Officer notifies of intention to sell stock

Price target increased by 8.1% to US$10.00

New minor risk - Share price stability

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

Consensus EPS estimates fall by 209%

New minor risk - Profitability

No longer forecast to breakeven

Aldeyra Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?

Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable

Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease

Consensus EPS estimates upgraded to US$0.18 loss

Forecast to breakeven in 2026

Consensus EPS estimates fall by 163%

Aldeyra Therapeutics, Inc. Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease

No longer forecast to breakeven

New minor risk - Profitability

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 04, 2024

New minor risk - Profitability

No longer forecast to breakeven

Forecast to breakeven in 2024

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease

CEO, President & Director recently sold US$581k worth of stock

CEO, President & Director notifies of intention to sell stock

Forecast to breakeven in 2024

New minor risk - Profitability

Forecast to breakeven in 2024

Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?

Consensus revenue estimates increase by 55%

Consensus revenue estimates increase by 57%

Aldeyra Therapeutics, Inc. Announces Positive Top-Line Results from A Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis

Consensus revenue estimates increase by 600%

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Consensus revenue estimates decrease by 82%, EPS upgraded

Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?

New minor risk - Market cap size

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Announces Update of U.S. Food and Drug Administration Relating to the New Drug Application for Reproxalap for the Treatment of the Signs and Symptoms of Dry Eye Disease

Consensus revenue estimates decrease by 61%, EPS upgraded

Price target decreased by 13% to US$17.86

CEO, President & Director exercised options and sold US$492k worth of stock

Frank R. Cruz Announces Securities Fraud Lawsuit Against Aldeyra Therapeutics, Inc

Consensus revenue estimates increase by 36%

Consensus revenue estimates decrease by 73%, EPS upgraded

Holzer & Holzer, LLC Files Class Action Lawsuit Against Aldeyra Therapeutics, Inc

Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX--629 in Patients with Chronic Cough

Consensus revenue estimates increase by 15%

Aldeyra Therapeutics, Inc. Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE--2 Trial of Reproxalap in Allergic Conjunctivitis

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 30, 2023

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

Consensus revenue estimates decrease by 41%, EPS upgraded

Price target increased by 8.4% to US$21.83

Aldeyra Therapeutics, Inc. Advances Investigational Oral RASP Modulator ADX--629 Into New Phase 2 Systemic Disease Trials

Aldeyra Therapeutics, Inc. Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease

Forecast to breakeven in 2025

Insufficient new directors

Aldeyra Therapeutics, Inc. Submits New Drug Application to the U.S. Food and Drug Administration for Adx-2191 for the Treatment of Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics, Inc. Announces Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial

Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA

Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?

Aldeyra Therapeutics, Inc. Achieves Primary Endpoint in Part 1 of Phase 3 Guard Trial of Adx-2191 in Proliferative Vitreoretinopathy

Aldeyra Therapeutics, Inc. Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA